Roche Announces Positive Phase II Results for Obesity and Type 2 Diabetes Drug Enicepatide

Roche has reported positive Phase II clinical trial results for its dual GLP-1/GIP receptor agonist, enicepatide, in individuals with type 2 diabetes and overweight or obesity. At the highest dose (24 mg), the drug achieved a mean HbA1c reduction of 2.65% at 48 weeks, indicating its potential for significant glycemic control. Interim data from this study will be presented at an upcoming medical meeting and shared with health authorities.